* Diatide Inc., of Londonderry, N.H., received $356,000 from theNational Institutes of Health to fund a second year of research undera Phase II Small Business Innovation Research grant for imagingagents to detect blood clots. Diatide develops radiopharmaceuticals.
* Parexel International Corp., of Boston, paid $20 million in stock tobuy a health care consulting firm, State and Federal Associates Inc.,of Washington. Parexel will add State and Federal's consulting andmarketing services to its contract research organization activities.
* Unigene Laboratories Inc., of Fairfield, N.J., began Phase III trialsof Fortical (salmon calcitonin) in the U.S. and U.K. for osteoporosis.The drug is being evaluated in an injectable form. Unigene recentlycompleted a Phase I study earlier this year for a calcitonin pill.
(c) 1997 American Health Consultants. All rights reserved.